Drugmaker Lilly Says Covid Treatment Slashed Hospitalization and Deaths

March 10, 2021

(Medical Xpress) – US drugmaker Eli Lilly’s combination of two synthetic antibodies reduced hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19 by 87 percent in trials, the company said Wednesday. The results come from a Phase 3 clinical trial of 769 people aged 12 and over with mild-to-moderate COVID-19, who were considered high-risk because of their age or underlying conditions.